Clicky

 

Intelligence » Top Posts » Latest Posts

Subscribe to get latest posts via email or subscribe to a RSS feed.

Pfizer's Xeljanz gets FDA nod as joint disease treatment

Friday, December 15, 2017 -- (Reuters) - U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease.

IU scientists discover way to make drug treatment more successful against malaria

Friday, December 15, 2017 -- Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to combat this deadly disease in humans.

Lilly partners with Rimidi on digital diabetes management tool

Friday, December 15, 2017 -- Pharmaceutical companies in the diabetes market are all investing in tech to help doctors and patients manage the condition. That means companies such as Lilly, Novo Nordisk, Sanofi and AstraZeneca will soon be competing not just on their medicine...

Loyola Medicine study finds high success rate for diabetic Charcot foot surgery

Friday, December 15, 2017 -- Nearly four out of five diabetic patients with severe cases of a disabling condition called Charcot foot were able to walk normally again following surgery, a Loyola Medicine study has found.

Intestinal Microbiome Linked To Pediatric Asthma

Friday, December 15, 2017 -- MedicalResearch.com Interview with: Anita Kozyrskyj, PhD, Professor, Dept Pediatrics Faculty of Medicine & Dentistry, University of Alberta Edmonton, AB   MedicalResearch.com: What is the background for this study? What are the main findings? Response: I was motivated to study the maternal … Continue reading →

Frequent Take-Out Food Linked To Increased Cholesterol and Obesity in Children

Friday, December 15, 2017 -- MedicalResearch.com Interview with: Dr. Angela S Donin Population Health Research Institute, St George’s University of London, London, UK  MedicalResearch.com: What is the background for this study? What are the main findings? Response: There are increasing numbers of takeaway outlets, particularly in deprived … Continue reading →

[News] San Antonio Breast Cancer Symposium 2017

Thursday, December 14, 2017 -- Debu Tripathy (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and colleagues presented an interim analysis of the randomised, phase 3, MONALEESA-2 trial, the first trial investigating the addition of cyclin D1/CDK4/6 inhibitor ribociclib to standard hormone therapy in women with premenopausal or perimenopausal, hormone receptor–positive (HR-positive), HER2-negative advanced breast cancer. 672 patients were randomly assigned (1:1) to ribociclib (600 mg per day, 3-weeks on, 1-week off; n=335) or placebo (n=337) in combination with tamoxifen (20 mg per day) or a nonsteroidal aromatase inhibitors (letrozole [2·5 mg per day] or anastrozole [1 mg per day]) plus goserelin (3·6 mg every 28 days).

[News] TAS-102 in metastatic colorectal cancer

Thursday, December 14, 2017 -- A new study has found that trifluridine/tipiracil (TAS-102)significantly increases overall survival compared with that for placebo in Asian patients with advanced colorectal cancer, irrespective of whether they have been exposed to biological therapy.

[Articles] Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Thursday, December 14, 2017 -- Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia.

[Comment] Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST

Thursday, December 14, 2017 -- Although Staphylococcus aureus bacteraemia is both common and potentially lethal, clinical decisions involving its treatment remain largely unencumbered by high-quality data.1 With the ARREST multicentre, randomised, double-blind, placebo-controlled trial, Guy Thwaites and colleagues2 have contributed high-quality evidence and addressed an unresolved question involving the role of adjunctive rifampicin in treatment regimens for patients with S aureus bacteraemia.

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Thursday, December 14, 2017 -- PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae New...

Familial Members Without Genetic Mutation Can Still Have Increased Risk of Melanoma

Thursday, December 14, 2017 -- MedicalResearch.com Interview with: Hildur Helgadottir, M.D., Ph.D. Department of Oncology Karolinska University Hospital MedicalResearch.com: What is the background for this study? What are the main findings? Response: Malignant melanoma of the skin is one of the fastest increasing cancer types … Continue reading →

Merck's Keytruda fails pivotal gastric cancer trial

Thursday, December 14, 2017 -- (Reuters) - Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer.

Higher Cholesterol in Kids Eating Regular Takeout Meals

Thursday, December 14, 2017 -- (MedPage Today) -- Fat mass index and sum of skinfolds also higher in British study

Families of dementia patients see positive effect of social robot seal

Thursday, December 14, 2017 -- (Reuters Health) - Paro, a robotic baby harp seal, seems to improve dementia patients’ mood and increase opportunities for communication with family members, according to a small study.

Evolution-guided adaptation of an adenylation domain substrate specificity to an unusual amino acid

Thursday, December 14, 2017 -- by Simon Vobruba, Stanislav Kadlcik, Radek Gazak, Jiri Janata Adenylation domains CcbC and LmbC control the specific incorporation of amino acid precursors in the biosynthesis of lincosamide antibiotics celesticetin and lincomycin. Both proteins originate from a common L-proline-specific ancestor, but LmbC was evolutionary adapted to use an unusual substrate, (2S,4R)-4-propyl-proline (PPL). Using site-directed mutagenesis of the LmbC substrate binding pocket and an ATP-[32P]PPi exchange assay, three residues, G308, A207 and L246, were identified as crucial for the PPL activation, presumably forming together a channel of a proper size, shape and hydrophobicity to accommodate the propyl side chain of PPL. Subsequently, we experimentally simulated the molecular evolution leading from L-proline-specific substrate binding pocket to the PPL-specific LmbC. The mere change

Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy

Thursday, December 14, 2017 -- by Keitaro Hase, Atsuhiro Kanda, Ikuyo Hirose, Kousuke Noda, Susumu Ishida (Pro)renin receptor [(P)RR], a new component of the tissue renin-angiotensin system (RAS), plays a crucial role in inflammation and angiogenesis in the eye, thus contributing to the development of proliferative diabetic retinopathy (PDR). In this study, we investigated systemic factors related to plasma levels of soluble form of (P)RR [s(P)RR] in patients with PDR. Twenty type II diabetic patients with PDR and 20 age-matched, non-diabetic patients with idiopathic macular diseases were enrolled, and plasma levels of various molecules were measured by enzyme-linked immunosorbent assays. Human retinal microvascular endothelial cells were stimulated with several diabetes-related conditions to evaluate changes in gene expression using real-time quantitative PCR. Of various systemic

Tumor necrosis factor-α antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis

Thursday, December 14, 2017 -- by Ji-Hye Kim, Ae Ri Kim, Yun Hui Choi, Sungil Jang, Gye-Hyeong Woo, Jeong-Heon Cha, Eun-Jung Bak, Yun-Jung Yoo Type 1 diabetes with periodontitis shows elevated TNF-α expression. Tumor necrosis factor (TNF)-α stimulates the expression of receptor activator of nuclear factor-κB ligand (RANKL) and sclerostin. The objective of this study was to determine the effect of TNF-α expression of osteocytic RANKL and sclerostin in type 1 diabetes rats with periodontitis using infliximab (IFX), a TNF-α antagonist. Rats were divided into two timepoint groups: day 3 and day 20. Each timepoint group was then divided into four subgroups: 1) control (C, n = 6 for each time point); 2) periodontitis (P, n = 6 for each time point); 3) diabetes

Diagnostic accuracy research in glaucoma is still incompletely reported: An application of Standards for Reporting of Diagnostic Accuracy Studies (STARD) 2015

Thursday, December 14, 2017 -- by Manuele Michelessi, Ersilia Lucenteforte, Alba Miele, Francesco Oddone, Giada Crescioli, Valeria Fameli, Daniël A. Korevaar, Gianni Virgili Background Research has shown a modest adherence of diagnostic test accuracy (DTA) studies in glaucoma to the Standards for Reporting of Diagnostic Accuracy Studies (STARD). We have applied the updated 30-item STARD 2015 checklist to a set of studies included in a Cochrane DTA systematic review of imaging tools for diagnosing manifest glaucoma. Methods Three pairs of reviewers, including one senior reviewer who assessed all studies, independently checked the adherence of each study to STARD 2015. Adherence was analyzed on an individual-item basis. Logistic regression was used to evaluate the effect of publication year and impact factor on adherence. Results We

Acne keloidalis nuchae in Asian: A single institutional experience

Thursday, December 14, 2017 -- by Kiyong Na, Sang Ho Oh, Sang Kyum Kim Acne keloidalis nuchae, a type of folliculitis involving the back of the neck, is common in black men, although rare cases have been reported in patients of other ethnicities. We analyzed the clinicopathological features of acne keloidalis nuchae in 17 Asians. Patients’ age at the time of presentation ranged from 20 to 69 years. Most patients experienced the disease over 2 years (range, 3 months–20 years); follow-up data were available for 11 (65%) patients (range, 2–95 months). Nine (53%) patients had comorbidities, but none had a history of other skin disease or a family history of acne keloidalis nuchae. Macroscopically, seven (41%) patients had multiple erythematous pustulopapular lesions, and 10